Oncotarget strategies for herpes simplex virus-1

Lumin Zhang, Tsurumi Tatsuya, Yukihiro Nishiyama

Research output: Contribution to journalArticlepeer-review

3 Scopus citations


The high level of manipulability of viral genome has set up HSV-1 to be an ideal viral vector for oncolytic virotherapy. In the past two decades, several oncolytic HSV-1 viruses have been successfully developed and assessed in animal studies. Accumulated evidences show that oncolytic HSV- 1 can efficiently infect many tumor cells and augment anti-tumor effect by induction of systemic innate and adaptive immune responses. Inspiring results have been accomplished in several phase I clinical trials for glioma, head and neck squeous cells carcinoma and Melanoma using oncolytic HSV- 1 viruses. More recently, oncovey, one of oncolytic HSV-1 viruses has been approved by FDA for the comprehensive evolution of its anti-tumor effects in phase III clinical trials. These promising studies encourage more efforts to be devoted to craft the new generation of oncolytic HSV-1. Herein, we will review and summarize the basic strategies to construct oncolytic HSV-1 viruses and their applications in cancer therapy.

Original languageEnglish
Pages (from-to)130-143
Number of pages14
JournalCurrent Gene Therapy
Issue number2
StatePublished - 1 Apr 2016
Externally publishedYes


  • Anti-tumor
  • Glioma
  • ICP34.5
  • Oncolytic HSV-1 virotherapy
  • Oncotarget


Dive into the research topics of 'Oncotarget strategies for herpes simplex virus-1'. Together they form a unique fingerprint.

Cite this